Highlights from the Week of 13th July 2026 - 20th July 2026

(FDA, Approval)

FDA approves Biogen's sBLA for once-weekly LEQEMBI IQLIK SC as an initiation dose to treat early Alzheimer's disease

(FDA, Approval)

FDA grants traditional approval to Novartis' FABHALTA, that slows kidney function decline in adults with IgAN

(FDA, Approval)

Merck receives FDA approval for LIPFENDRA tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH

(FDA, Approval)

Celcuity obtains FDA approval for REVTORPYK to treat HR+, HER2- locally advanced or metastatic breast cancer

(EU, Approval)

EC approves Boehringer Ingelheim's JASCAYD to treat adults with IPF and PPF

(EU, Approval)

Novo Nordisk's WEGOVY 25 mg pill gets EC marketing authorization to treat adults with obesity or overweight

(EU, Approval)

AbbVie's Allergan Aesthetics receives EC approval for BOEY to temporarily improve the appearance of glabellar lines in adults

(FDA, Priority Review)

Roche gets Priority Review from the FDA for its sBLA GAZYVA to treat primary membranous nephropathy

(Acquisition)

GSK acquires Nuvalent, adding three lung cancer assets to its oncology portfolio in a transaction of approximately $10.6B

(Collaboration)

AstraZeneca collaborates with Dizal Pharmaceutical to develop and commercialise ZEGFROVY for lung cancer, making an upfront payment of $600M

(Collaboration)

Samsung Bioepis and Organon collaborate to develop, manufacture and commercialize a biosimilar in Australia, expanding the biosimilar portfolio and widening global access

(Collaboration)

Innovent Biologics collaborates with Spero Therapeutics to develop, research, manufacture and commercialize IBI355 globally, with an approximate upfront payment of US$1.1B

(Phase 3, Results)

Takeda's Ph3 LATITUDE PsO 3001 and 3002 studies evaluating TAK-279 demonstrates consistent high rates of skin clearance in psoriasis, across hard-to-treat, high-impact sites, compared with placebo, based on PASI 75

(Phase 3, Results)

Merck's Ph3 KEYNOTE-C93 trial evaluating KEYTRUDA met its primary and secondary endpoints of PFS and ORR, respectively, compared to platinum doublet chemotherapy in advanced or recurrent endometrial cancer with dMMR